Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

@article{Basilico2013TivantinibD,
  title={Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.},
  author={Cristina Basilico and Selma Pennacchietti and Elisa Vigna and Cristina Chiriaco and Sabrina Arena and Alberto Bardelli and Donatella Valdembri and Guido Serini and Paolo Michieli},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 9},
  pages={
          2381-92
        }
}
PURPOSE MET, the high-affinity receptor for hepatocyte growth factor, is frequently deregulated in human cancer. Tivantinib (ARQ197; Arqule), a staurosporine derivative that binds to the dephosphorylated MET kinase in vitro, is being tested clinically as a highly selective MET inhibitor. However, the mechanism of action of tivantinib is still unclear. EXPERIMENTAL DESIGN The activity of tivantinib was analyzed in multiple cellular models, including: cells displaying c-MET gene amplification… CONTINUE READING
Tweets
This paper has been referenced on Twitter 23 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 75 CITATIONS

FILTER CITATIONS BY YEAR

2013
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 10 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Breast cancerderived bonemetastasis canbe effectively reduced through speci fi c c - MET inhibitor tivantinib ( ARQ 197 ) and shRNA c - MET knockdown

  • S Previdi, BrogginiM FranceDS
  • Mol Cancer Ther
  • 2012

FlattenKS,PoirierGG,KaufmannSH.Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

  • AG Patel, DeLorenzoSB
  • Clin Cancer Res
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…